Allergic Conjunctivitis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Allergic conjunctivitis is one of the most ordinary forms of conjunctivitis. Allergic conjunctivitis causes red, watery, itchy, or gritty eyes. It usually happens when a person's eyes contact with an allergen, a substance that makes the body's immune system overreacting. Symptoms arise due to the body's overreacting immune system, which causes histamine and other active substances to be released through mast cells. The vision becomes sore and inflamed. The nerve endings are irritated when blood vessels dilate or expand. As a result, tears are secreted more frequently. Typically, the condition is not painful and does not cause light sensitivity in the eyes. Allergic conjunctivitis is caused by an allergen-induced inflammatory response in which allergens interact with IgE bound to sensitized mast cells, resulting in clinical allergic manifestations of the eyes. AC is the only ocular disease caused entirely by a type I allergic reaction. In sensitized individuals, T2 cells release pro-inflammatory cytokines (IL-3, IL-4, IL-5, IL-13) that stimulate the B cells' immunoglobulin E (IgE) production. The IgE binds to mast cells' membranes, and subsequent cross-linking by their allergens causes mast cell degranulation and the release of preformed (histamine, tryptase) and newly formed mediators (leukotrienes, prostaglandins).

 

The prevalence of Allergic conjunctivitis ranges from 32 MN to 35 MN in the US population.

 

The competitive landscape of Allergic Conjunctivitis includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Allergic Conjunctivitis across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Allergic Conjunctivitis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Allergic Conjunctivitis– Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          TD-9855           Theravance Biopharma  Phase 2

2          MG01CI            Alcobra Ltd.      Phase 3

3          Centanafadine Hydrochloride     Otsuka Pharmaceutical Development     Phase 3

4          Methylphenidate MPH   Mensia Technologies SA           Phase 2

5          Lisdexamfetamine         Shire    Phase 2

6          V81444 Vernalis (R&D) Ltd        Phase 2

7          ND0801            NeuroDerm Ltd. Phase 2

8          Dasotraline       Sunovion          Phase 3

9          PDC-1421 Capsule        BioLite, Inc.       Phase 2

10        SPN-812           Supernus Pharmaceuticals, Inc. Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more